Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01105312 · ClinicalTrials.gov registry record · Phase 1
Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer
A Phase 1 study, sponsored by Alliance for Clinical Trials in Oncology.
- Completed
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
NCT01105312 is a Phase 1 study that has completed, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 28 participants.
The verdict
NCT01105312, a Phase 1 study, has completed, sponsored by Alliance for Clinical Trials in Oncology.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
RATIONALE: Panobinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Estrogen can cause the growth of breast cancer cells. Hormone therapy using letrozole may fight breast cancer by lowering the amount of estrogen the body makes. Giving panobinostat together with letrozole may be an effective treatment for breast cancer. PURPOSE: This phase I/II trial is studying the side effects and best dose of panobinostat when given together with letrozole and to see how well it works in treating patients with metastatic breast cancer.
Interventions
- GENETIC microarray analysis
- DRUG panobinostat
- DRUG letrozole
- GENETIC RNA analysis
- GENETIC reverse transcriptase-polymerase chain reaction
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2010-09 |
| Est. Completion | 2013-09-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01105312
The ClinicalTrials.gov registry entry for NCT01105312 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alliance for Clinical Trials in Oncology, which has 446 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which microarray analysis is the first listed.
NCT01105312 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01105312 about?
NCT01105312 is a clinical study titled "Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer". RATIONALE: Panobinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Estrogen can cause the growth of breast cancer cells. Hormone therapy using letrozole may fight breast cancer by lowering the amount of estrogen the body makes. Giving panobinostat toge...
What is the current status of trial NCT01105312?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2010-09. Estimated completion is 2013-09-03.
What interventions are being tested in trial NCT01105312?
The interventions under investigation include: microarray analysis (GENETIC), panobinostat (DRUG), letrozole (DRUG), RNA analysis (GENETIC), reverse transcriptase-polymerase chain reaction (GENETIC).
Who is sponsoring clinical trial NCT01105312?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.